Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone617-807-6600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.62 million
Profitability
Miscellaneous
Employees83
OptionableOptionable
Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions
What is Paratek Pharmaceuticals' stock symbol?
Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."
How were Paratek Pharmaceuticals' earnings last quarter?
Paratek Pharmaceuticals Inc (NASDAQ:PRTK) released its quarterly earnings data on Thursday, August, 2nd. The specialty pharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.92) by $0.02. The specialty pharmaceutical company earned $0.04 million during the quarter, compared to analyst estimates of $0.10 million. Paratek Pharmaceuticals had a negative net margin of 2,155.03% and a negative return on equity of 132.55%. View Paratek Pharmaceuticals' Earnings History.
When is Paratek Pharmaceuticals' next earnings date?
What price target have analysts set for PRTK?
10 brokers have issued 12 month target prices for Paratek Pharmaceuticals' shares. Their forecasts range from $13.00 to $50.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $26.25 in the next twelve months. This suggests a possible upside of 263.6% from the stock's current price. View Analyst Price Targets for Paratek Pharmaceuticals.
What is the consensus analysts' recommendation for Paratek Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Paratek Pharmaceuticals.
What are Wall Street analysts saying about Paratek Pharmaceuticals stock?
Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (2/14/2019)
- 2. LADENBURG THALM/SH SH analysts commented, "We are transferring coverage of Paratek Pharmaceuticals, maintaining a Buy rating and $18 price target. Paratek received FDA approval for two novel antibiotics. Nuzyra (omadacycline) was approved in both acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Additionally, Seysara (sarecycline) was approved for inflammatory acne, with U.S. commercialization exclusively licensed to Rated) (sub- licensed to Not Rated). Paratek retains Seysara’s ex-U.S. rights." (12/18/2018)
- 3. Cantor Fitzgerald analysts commented, ". Post a quarter of solid execution and ahead of the AdCom on 8/8/18 as well as what we expect to be an approval for omadacycline, we are reiterating our OW rating and 12-month price target of $50. We like PRTK because it is well capitalized (including the convertible debt raise and incoming milestones), de-risked with three positive Phase 3 trials (in an oral only skin trial) and has a diversified pipeline (omadacycline for cUTI, uUTI, Sarecycline, etc.). We anticipate two product approvals for PRTK in 2H18, omadacycline and Sarecycline." (8/2/2018)
Has Paratek Pharmaceuticals been receiving favorable news coverage?
Media coverage about PRTK stock has been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are some of Paratek Pharmaceuticals' key competitors?
Some companies that are related to Paratek Pharmaceuticals include MacroGenics (MGNX), Homology Medicines (FIXX), CannTrust (CNTTF), Advanz Pharma (CXRXF), Retrophin (RTRX), Athenex (ATNX), Radius Health (RDUS), ImmunoGen (IMGN), CytomX Therapeutics (CTMX), Inflarx (IFRX), G1 Therapeutics (GTHX), Apellis Pharmaceuticals (APLS), Arvinas (ARVN), Y-mAbs Therapeutics (YMAB) and Evolus (EOLS).
Who are Paratek Pharmaceuticals' key executives?
Paratek Pharmaceuticals' management team includes the folowing people:
- Mr. Michael F. Bigham, Chairman & CEO (Age 61)
- Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 60)
- Mr. Douglas W. Pagán, Chief Financial Officer (Age 47)
- Mr. William M. Haskel, Sr. VP, Gen. Counsel & Corp. Sec. (Age 57)
- Mr. Adam Woodrow, Chief Commercial Officer & VP (Age 52)
Who are Paratek Pharmaceuticals' major shareholders?
Paratek Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include General American Investors Co. Inc. (1.45%), Northern Trust Corp (1.28%), Water Island Capital LLC (0.99%), Royce & Associates LP (0.99%), Geode Capital Management LLC (0.96%) and Fosun International Ltd (0.71%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Michael Bigham, Robert S Radie, Thomas John Dietz and William M Haskel. View Institutional Ownership Trends for Paratek Pharmaceuticals.
Which major investors are selling Paratek Pharmaceuticals stock?
PRTK stock was sold by a variety of institutional investors in the last quarter, including Water Island Capital LLC, Royce & Associates LP, Two Sigma Investments LP, Trellus Management Company LLC, Northern Trust Corp, New York State Common Retirement Fund, Wedbush Securities Inc. and Hilltop Holdings Inc.. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh, Michael Bigham, Thomas John Dietz and William M Haskel. View Insider Buying and Selling for Paratek Pharmaceuticals.
Which major investors are buying Paratek Pharmaceuticals stock?
PRTK stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd, Teton Advisors Inc., Gamco Investors INC. ET AL, Gabelli Funds LLC, Virtu Financial LLC, General American Investors Co. Inc., Telemetry Investments L.L.C. and Quinn Opportunity Partners LLC. View Insider Buying and Selling for Paratek Pharmaceuticals.
How do I buy shares of Paratek Pharmaceuticals?
Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Paratek Pharmaceuticals' stock price today?
One share of PRTK stock can currently be purchased for approximately $7.22.
How big of a company is Paratek Pharmaceuticals?
Paratek Pharmaceuticals has a market capitalization of $232.06 million and generates $12.62 million in revenue each year. The specialty pharmaceutical company earns $-89,060,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis. Paratek Pharmaceuticals employs 83 workers across the globe.
What is Paratek Pharmaceuticals' official website?
How can I contact Paratek Pharmaceuticals?
Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]
MarketBeat Community Rating for Paratek Pharmaceuticals (NASDAQ PRTK)
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
